Company profile
Enzolytics Inc.
OTC: ENZC · Healthcare · Biotechnology
#1 of 1,422 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 36
v0.1 · 5/100 weight · pillars only
↑ listing tenure, Altman-Z · ↓ workforce scale, filing timeliness
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
—
Employees
1
as of 2026-08-24
Market cap
$2.9M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
No filed financials — private or non-XBRL filer.
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Enzolytics Inc.’s financial profile?
Enzolytics Inc. has no structured financials on file — private or non-XBRL filer.
Peers · Healthcare
MetaVia Inc.——Standard Dental Labs Inc.——TransCode Therapeutics, Inc.——FibroBiologics, Inc. Common Stock——Strainsforpains, Inc.——Accustem Sciences Inc.——Neighbors
Collin →Key facts
CEOSteven Sharabura
SectorHealthcare
IndustryBiotechnology
HeadquartersPlano, TX
ExchangeOTC: ENZC
Employees1
IPO date2009-04-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.